SNAC

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

DiabetesDiabetes Mellitus, Type 2Healthy

Phase 1

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

CompletedNCT02845219

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2016-07-31End: 2016-12-31Updated: 2017-06-07

A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.

CompletedNCT02911870

Novo Nordisk A/SHealthy

Start: 2016-09-23End: 2017-05-11Updated: 2018-01-12

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

CompletedNCT02920385

Novo Nordisk A/SDiabetes, Healthy

Start: 2016-10-10End: 2017-06-16Updated: 2017-12-14

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

CompletedNCT03010475

Novo Nordisk A/SDiabetes, Healthy

Start: 2017-01-05End: 2017-08-09Updated: 2017-12-20

Related Papers

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.

2021-09-0113 citations

Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.

2021-07-282 citations